Allergen-specific immunotherapy and mRNA vaccines
Affiliated HospitalPeking Union Medical College Hospital, Chinese Academy of Medical Sciences
→
Research areas: Novel immunotherapy strategies for allergic airway inflammation, mechanisms and clinical translation of allergen-specific immunotherapy.
Cutting-edge technologies: Led the development of novel allergen-specific immunotherapy strategies based on mRNA vaccine technology, and constructed a lipid nanoparticle delivery system encoding Der p 1/Der p 2. Led a multicenter retrospective study of house dust mite allergen preparations for the treatment of allergic rhinitis with multiple allergies, finding that a higher level of fungal allergy is a risk factor for lower efficacy in patients with multiple allergies.
Specializes in treating: allergic rhinitis, allergic asthma, dust mite allergy, and immunotherapy for multiple sensitizations.
Academic Highlights and Core Values: Currently serving as the Director of the Department of Allergy, Deputy Director of the National Medical Quality Control Center for Immunology (including Allergy) (under construction), and a member of the Chinese Medical Association's Allergy Branch. As the corresponding author, he has published groundbreaking findings on mRNA immunotherapy in journals such as *Molecular Therapy*, propelling allergen-specific immunotherapy from the era of crude extracts to the era of genetic engineering.